Reviva Pharmaceuticals stock drops amid FDA trial feedback

Reviva Pharmaceuticals Holdings Inc's stock plummeted by 51.03%, crossing below the 5-day SMA, as the company faces uncertainty regarding its clinical trials.

The decline follows cautious feedback from the FDA, which indicated that Reviva must conduct a second Phase 3 trial for brilaroxazine to gather additional efficacy data. This news has raised concerns about the company's financing and development timeline, leading to a significant drop in stock price, which fell 48.54% to $0.30 in premarket trading, nearing its 52-week low of $0.25.

This situation reflects the market's apprehension about Reviva's clinical progress and the potential implications for its future, particularly as it seeks to secure funding for the new trial while addressing unmet medical needs.